Amanta Healthcare IPO Subscription Status – Day 1 Update
Amanta Healthcare IPO witnessed strong investor interest, being subscribed 4.62 times by the end of Day 1 (till 5:00 PM, September 1, 2025).
- Qualified Institutional Buyers (QIBs): 0.04x
- Non-Institutional Investors (NIIs): 5.82x
- Retail Individual Investors (RIIs): 6.72x
The IPO received 3,23,16,354 bids against the issue size of 70,00,000 shares, indicating exceptional demand from retail and NII investors.
About Amanta Healthcare Limited
- Incorporated: December 1994
- Industry: Pharmaceuticals and Medical Devices
- Core Products:
- Sterile liquid products (mainly parenterals) like IV fluids, diluents, eye drops, and respiratory care solutions.
- Medical devices segment: irrigation solutions, first-aid items, and eye lubricants.
- Technologies Used: Advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM).
- Business Divisions: National Sales, International Sales, and Product Partnerships.
- Distribution Network: Over 320 distributors and stockists across India.
- Employee Strength: 1,718 (as of March 31, 2025).
The company is well-positioned in the domestic and international pharmaceutical markets, with over 45 generic products under its own brand.
Amanta Healthcare Financial Performance (₹ in Crores)
- Revenue slightly declined 2.1% YoY, primarily due to pricing pressure in domestic markets.
- Net profit surged nearly 3 times, reflecting improved operational efficiency and cost optimization.
- Net margins improved from 1.29% → 3.80%, indicating better profitability despite stable revenue.
Amanta Healthcare IPO GMP
As of September 1, 2025, the Grey Market Premium (GMP) stood at ₹29.
- Issue Price: ₹126
- GMP Price: ₹155 (₹126 + ₹29)
- Expected Listing Gain: ~23%
The strong GMP indicates robust investor confidence, especially among retail and non-institutional investors.
Key Insights
- Day 1 oversubscription of 4.62x shows strong investor appetite.
- Retail investors were the primary contributors to high demand.
- The company’s improved net margins and profit growth highlight financial stability and operational efficiency.
- GMP suggests healthy listing gains, making the IPO attractive for short-term investors.
